Is Retatrutide Legal in Australia?

The short answer

Retatrutide is not an approved medicine in Australia. It is not listed on the Australian Register of Therapeutic Goods (ARTG), which means the Therapeutic Goods Administration (TGA) has not registered it for any therapeutic use. At the time of writing it is an investigational molecule still in clinical trials, so no Australian pharmacy can dispense it and no Pharmaceutical Benefits Scheme subsidy applies to it.

Because it is not an approved therapeutic good, retatrutide material offered in Australia is generally handled on a research-use-only basis, meaning it is intended for laboratory and analytical work rather than for human or animal use. This article explains the regulatory picture neutrally so you understand where retatrutide sits and what due diligence matters for buyers of research compounds.

What retatrutide is

Retatrutide is an investigational peptide being developed by the pharmaceutical company Eli Lilly. In scientific terms it is described as a triple hormone receptor agonist, meaning the molecule is designed to interact with three receptors at once: the GLP-1 receptor, the GIP receptor and the glucagon receptor. This triple-agonist design is the main reason it draws research interest, because it is structurally distinct from single or dual agonists in the same broad class.

It is useful to place retatrutide alongside other molecules that are frequently discussed in the same conversations. For background on related single and dual agonists, see our neutral overviews of tirzepatide and semaglutide. For a general profile of this molecule itself, see our retatrutide reference page.

tirzepatide semaglutide retatrutide

Where retatrutide sits in clinical development

Retatrutide is not a finished, approved product. Public information from Eli Lilly indicates the molecule has progressed into late-stage (Phase 3) clinical trials across several research programmes. Clinical trials are structured studies that investigate how an investigational compound behaves under controlled conditions and under medical supervision. They are run to generate the data that regulators later assess.

It is important to describe this neutrally. Clinical trials study what happens in a controlled research setting. They do not establish that a compound is safe, approved or appropriate for general use, and trial-stage status is not the same as regulatory approval. Until a regulator completes its own assessment and grants registration, a molecule remains investigational.

Eli Lilly has publicly signalled that regulatory filings are expected from 2027 onward in some markets. Any Australian assessment would follow the TGA's own independent process and its own timeline. None of that has occurred at the time of writing, so retatrutide's status in Australia remains unapproved and investigational.

TGA and ARTG status in Australia

In Australia, therapeutic goods that are approved for supply are entered on the Australian Register of Therapeutic Goods. Retatrutide does not have an ARTG entry. The absence of an ARTG entry reflects that it has not been evaluated and registered as a medicine here.

Because there is no ARTG entry, several things follow in a straightforward way. No Australian pharmacy can lawfully dispense retatrutide as a registered medicine, there is no approved product information, and there is no subsidised access pathway. The conventional, lawful way a person in Australia might encounter retatrutide in a clinical context is through enrolment in an approved clinical trial at a participating site, which is a tightly controlled and supervised setting.

How the Poisons Standard and scheduling apply

Australia classifies medicines and poisons through the Poisons Standard, also called the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). Approved members of the broader GLP-1 class of medicines, such as registered prescription products, are Schedule 4 substances, which means prescription-only medicines that require a prescription and pharmacist dispensing.

Retatrutide itself does not currently appear as a named entry in the Poisons Standard. It is worth stating clearly that the absence of a specific named entry is not the same as a substance being unregulated or freely available. The Therapeutic Goods Act framework still governs how therapeutic claims can be made and how products can be supplied, and an unapproved status carries its own constraints. The accurate, conservative summary is that retatrutide is unapproved and investigational, and nothing about that status makes it an approved consumer product.

Anti-doping and sport

Athletes who fall under anti-doping rules should be aware that investigational and non-approved substances can carry specific implications. The World Anti-Doping Agency (WADA) framework includes category S0, which covers pharmacological substances that have no current approval by any government regulatory health authority for human therapeutic use.

Category S0 is described as applying to substances such as those still in clinical development. Because retatrutide is not approved by any regulator for human therapeutic use at the time of writing, athletes and support staff bound by anti-doping rules should treat any non-approved substance with caution and seek guidance from Sport Integrity Australia or the relevant anti-doping authority. This paragraph is informational and is not advice on use.

What research-use-only means and buyer due diligence

Research-use-only is a framing that indicates a material is intended for laboratory, analytical or educational research work rather than for human or animal consumption. When a compound is not registered as a therapeutic good, this framing signals that it has not been through the approval process that medicines undergo and should not be treated as a medicine.

For anyone sourcing research compounds in Australia, due diligence centres on documentation and provenance rather than on claims about outcomes. Reasonable checks include reviewing labelling and intended-use statements, confirming identity and purity documentation, and understanding storage and handling expectations. A certificate of analysis and independent testing are the usual touchpoints here.

For a broader walkthrough of sensible checks when evaluating research peptides, see our research peptides buyer's guide. For documentation and testing specifically, see our explainers on reading a certificate of analysis and on third-party tested peptides. For handling, our guide on storing research peptides covers the basics.

• Confirm the product is labelled and described as research-use-only, not for human or animal use
• Look for identity and purity documentation such as a certificate of analysis
• Check whether independent, third-party testing is available
• Understand storage and handling expectations before purchase
• Remember that unapproved status means no therapeutic claims should be relied upon

research peptides buyer's guide reading a certificate of analysis third-party tested peptides storing research peptides

The bottom line

Retatrutide is an investigational triple-agonist molecule in late-stage clinical trials and is not a TGA-approved medicine in Australia. It is not on the ARTG, no pharmacy can dispense it as a registered product, and there is no subsidised pathway. Material offered in Australia is generally handled on a research-use-only basis for laboratory work rather than for human or animal use.

Regulatory status can change over time as assessments progress, so the accurate position today is simply this: unapproved, investigational and research-use-only. Anyone evaluating research compounds should prioritise documentation, provenance and honest labelling, and should keep in mind that trial-stage status is not regulatory approval.